close

Agreements

Date: 2011-11-03

Type of information: Production agreement

Compound: adenoviral vector expressing TIMP3 gene

Company: Ark Therapeutics (UK) University of Glasgow's Institute of Cardiovascular and Medical Sciences (UK)

Therapeutic area: Cardiovascular diseases

Type agreement:

manufacturing
production

Action mechanism:

Disease: vein graft failure associated with coronary artery bypass surgery

Details:

Ark Therapeutics has signed a manufacturing agreement with University of Glasgow\'s Institute of Cardiovascular and Medical Sciences under which Ark will provide full manufacturing and related services to support the development of the Institute's gene-therapy programme for the treatment of vein graft failure associated with coronary artery bypass surgery. Ark will manufacture for University of Glasgow cGMP grade adenoviral vector expressing TIMP3 gene to be administered ex vivo to vein grafts at the time of coronary artery bypass surgery in the University's first-in-man Phase I/II trial to reduce vein graft failure.

Financial terms:

Financial details of the agreement were not disclosed.

Latest news:

Is general: Yes